S108: A SYSTEMATIC POST-MARKETING (PM) REVIEW OF RARE INFUSION-RELATED REACTIONS (IRRS) PRESENTING AS PAIN EVENTS DURING OR AFTER CRIZANLIZUMAB INFUSION IN PATIENTS WITH SICKLE CELL DISEASE (SCD)

• J Kanter,
• A Shah,
• V Joshi,
• H Mehta,
• M Levine,
• U Arunagiri,
• J Paulose,
• B Donohue,
• A Scalera,
• D Manwani

Affiliations

J Kanter

1 University of Alabama, Birmingham, UNITED STATES

A Shah

2 Novartis Pharmaceuticals Corporation, East Hanover, UNITED STATES

V Joshi

3 Novartis Healthcare Private Limited, Hyderabad, INDIA

H Mehta

3 Novartis Healthcare Private Limited, Hyderabad, INDIA

M Levine

2 Novartis Pharmaceuticals Corporation, East Hanover, UNITED STATES

U Arunagiri

2 Novartis Pharmaceuticals Corporation, East Hanover, UNITED STATES

J Paulose

2 Novartis Pharmaceuticals Corporation, East Hanover, UNITED STATES

B Donohue

2 Novartis Pharmaceuticals Corporation, East Hanover, UNITED STATES

A Scalera

2 Novartis Pharmaceuticals Corporation, East Hanover, UNITED STATES

D Manwani

4 Albert Einstein College of Medicine, The Children’s Hospital at Montefiore, New York, UNITED STATES